These studies suggest complex relationships exist between HIF1α, VEGF, and EGFR, so the combination of one or more inhibitors of HIF1α, VEGR, EGFR with lenvatinib may enhance their therapeutic effect in hepatocellular carcinoma (48). The gene discussed is HIF1A; the disease is hepatocellular carcinoma.